Find recruiting clinical trials for melanoma in the UK � from adjuvant treatment after surgery to advanced and metastatic disease. See your treatment pathway and where trials fit in.
Free to use � Live data from ClinicalTrials.gov � Updated hourly
Answer a few questions about your condition and we'll match you to the most relevant clinical trials.
See where clinical trials fit into your treatment journey
Treatment after complete resection to reduce recurrence risk
Standard: Immunotherapy (Nivolumab or Pembrolizumab) or Targeted therapy (Dabrafenib + Trametinib for BRAF+)
Initial treatment for unresectable or metastatic disease
Standard: Nivolumab + Ipilimumab (combination) or Pembrolizumab monotherapy
After progression on immunotherapy � clinical trials especially important
Standard: Tumour-infiltrating lymphocyte (TIL) therapy, targeted therapy (BRAF+), or clinical trial
Treatment before surgery for resectable disease
Standard: Emerging � immunotherapy before surgery is an active trial area
About 40-50% of melanomas carry a BRAF V600 mutation. These patients are eligible for targeted therapy with BRAF/MEK inhibitor combinations (dabrafenib + trametinib, vemurafenib + cobimetinib).
PD-L1 is a checkpoint protein that helps predict immunotherapy response. Higher expression may indicate better response to anti-PD-1 therapy, though benefit is not limited to PD-L1 positive tumours.
About 15-20% of melanomas have NRAS mutations. These tumours tend to be more aggressive and don't respond to BRAF inhibitors. Clinical trials are especially important for this group.
Loading trials from ClinicalTrials.gov...
Dramatically. Immune checkpoint inhibitors (Nivolumab, Pembrolizumab, Ipilimumab) have transformed advanced melanoma from a terminal diagnosis to a treatable condition. Trials now explore combinations and newer immunotherapies.
Yes. Adjuvant trials test whether immunotherapy or targeted therapy after surgery can prevent recurrence. Neoadjuvant trials (treatment before surgery) are also showing excellent results.
About 50% of melanomas have BRAF mutations. Targeted therapy (BRAF + MEK inhibitors like Dabrafenib + Trametinib) blocks these specific pathways. Trials study new combinations and sequences.
Use our search above to find trials that match your condition and location. Review the eligibility criteria carefully.
Talk to your GP or specialist about any trials you are interested in. They can help determine if a trial is appropriate for you.
Reach out to the trial team directly using the contact information on the ClinicalTrials.gov listing. They will guide you through screening.
If you meet the criteria and decide to participate, you will go through informed consent and begin the trial process.